Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research Post published:July 25, 2025 Post category:Psychedelic Bulletin/Pα+
June 2025 Psychedelic Patent Update Post published:July 24, 2025 Post category:Psychedelic Patent Analysis/Pα+
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1) Post published:July 23, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? Post published:July 14, 2025 Post category:Psychedelic Bulletin/Pα+
From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook Post published:July 7, 2025 Post category:Interviews/Pα+
Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model Post published:July 1, 2025 Post category:Analysis/News/Pα+
Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans Post published:July 1, 2025 Post category:Interviews/Pα+
Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout Post published:June 28, 2025 Post category:Analysis/News/Pα+